Laura H. Porter

968 total citations
15 papers, 297 citations indexed

About

Laura H. Porter is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Laura H. Porter has authored 15 papers receiving a total of 297 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 5 papers in Oncology and 4 papers in Molecular Biology. Recurrent topics in Laura H. Porter's work include Prostate Cancer Treatment and Research (11 papers), Prostate Cancer Diagnosis and Treatment (5 papers) and Immunotherapy and Immune Responses (4 papers). Laura H. Porter is often cited by papers focused on Prostate Cancer Treatment and Research (11 papers), Prostate Cancer Diagnosis and Treatment (5 papers) and Immunotherapy and Immune Responses (4 papers). Laura H. Porter collaborates with scholars based in Australia, United States and United Kingdom. Laura H. Porter's co-authors include Gail P. Risbridger, Renea A. Taylor, Mitchell G. Lawrence, David Clouston, Mark Frydenberg, Declan G. Murphy, Carmel Pezaro, Damien Bolton, Dragan Ilić and Ross D. Hannan and has published in prestigious journals such as Clinical Cancer Research, Science Translational Medicine and European Urology.

In The Last Decade

Laura H. Porter

14 papers receiving 295 citations

Peers

Countries citing papers authored by Laura H. Porter

Since Specialization

Citations

This map shows the geographic impact of Laura H. Porter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura H. Porter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura H. Porter more than expected).

Fields of papers citing papers by Laura H. Porter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laura H. Porter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura H. Porter. The network helps show where Laura H. Porter may publish in the future.

Co-authorship network of co-authors of Laura H. Porter

This figure shows the co-authorship network connecting the top 25 collaborators of Laura H. Porter. A scholar is included among the top collaborators of Laura H. Porter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laura H. Porter. Laura H. Porter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Targeting PTPN2 enhances human CAR T cell efficacy and the development of long-term memory in mouse xenograft models 2025 ·Science Translational Medicine ·Xin Du, Pei Kee Goh, Chenkai Ma, (unknown), (unknown), Laura H. Porter, Brendan E. Russ, Katherine D. Cummins, Kevin Sek, Clare Y. Slaney, Andrew M. Scott, Jane Oliaro, Paul J. Neeson, Gail P. Risbridger, Renea A. Taylor, Joseph A. Trapani, Stephen T. Turner, Phillip K. Darcy, Florian Wiede, Tony Tiganis	0
2	Left out in the cold: Moving beyond hormonal therapy for the treatment of immunologically cold prostate cancer with CAR T cell immunotherapies 2024 ·The Journal of Steroid Biochemistry and Molecular Biology ·Laura H. Porter, (unknown), Gail P. Risbridger, Natalie L. Lister, Renea A. Taylor	3
3	How long do nosocomial pathogens persist on inanimate surfaces? A scoping review 2024 ·Journal of Hospital Infection ·Laura H. Porter, (unknown), Brett Mitchell, Adam Jenney, Matthew C. Kiernan, David Brewster, Philip L. Russo	20
4	Co‐targeting BET, CBP, and p300 inhibits neuroendocrine signalling in androgen receptor‐null prostate cancer 2024 ·The Journal of Pathology ·(unknown), Shivakumar Keerthikumar, Susanne Ramm, Daisaku Ashikari, (unknown), Birunthi Niranjan, Shelley Hedwards, Laura H. Porter, David L. Goode, Kaylene J. Simpson, Renea A. Taylor, Gail P. Risbridger, Mitchell G. Lawrence	7
5	The future of patient-derived xenografts in prostate cancer research 2023 ·Nature Reviews Urology ·Mitchell G. Lawrence, Renea A. Taylor, (unknown), Lisa S. Ang, Ashlee K. Clark, David L. Goode, Laura H. Porter, Clémentine Le Magnen, Nora M. Navone, Jack A. Schalken, Yuzhuo Wang, Wytske M. van Weerden, Eva Corey, John T. Isaacs, Peter S. Nelson, Gail P. Risbridger	8
6	CX-5461 Sensitizes DNA Damage Repair–proficient Castrate-resistant Prostate Cancer to PARP Inhibition 2021 ·Molecular Cancer Therapeutics ·Mitchell G. Lawrence, Laura H. Porter, (unknown), David Pook, Jeremy Grummet, Carmel Pezaro, Shahneen Sandhu, Susanne Ramm, (unknown), Andrew Bakshi, David L. Goode, Elaine Sanij, Richard B. Pearson, Ross D. Hannan, Kaylene J. Simpson, Renea A. Taylor, Gail P. Risbridger, Luc Furic	17
7	Preclinical Evidence of the Efficacy of Lewis Y Car T Cells in Patient-Derived Models of Prostate Cancer 2021 ·Journal of the Endocrine Society ·Gail P. Risbridger, Laura H. Porter, Joe Jiang Zhu, David J. Byrne, Natalie L. Lister, Arun Azad, Michael S. Hofman, Ian Vela, Renea A. Taylor, Paul J. Neeson, Phillip K. Darcy, Joseph A. Trapani	1
8	Hidden clues in prostate cancer – Lessons learned from clinical and pre-clinical approaches on diagnosis and risk stratification 2021 ·Cancer Letters ·Roxanne Toivanen, Laura H. Porter, Zhuoer Li, David Clouston, Gail P. Risbridger, Renea A. Taylor	4
9	Androgen receptor enhancer amplification in matched patient‐derived xenografts of primary and castrate‐resistant prostate cancer 2021 ·The Journal of Pathology ·Laura H. Porter, Andrew Bakshi, David Pook, (unknown), David Clouston, John Kourambas, (unknown), David L. Goode, Gail P. Risbridger, Renea A. Taylor, Mitchell G. Lawrence	13
10	Knowing what’s growing: Why ductal and intraductal prostate cancer matter 2020 ·Science Translational Medicine ·Mitchell G. Lawrence, Laura H. Porter, David Clouston, Declan G. Murphy, Mark Frydenberg, Renea A. Taylor, Gail P. Risbridger	27
11	PARP inhibitor and CX-5461 combination therapy as a novel treatment strategy for castrate-resistant prostate cancer 2019 ·Laura H. Porter, Mitchell G. Lawrence, (unknown), Shahneen Sandhu, Hong Wang, David Pook, Elaine Sanij, Richard B. Pearson, Ross D. Hannan, Luc Furic, Renea A. Taylor, Gail P. Risbridger	2
12	Intraductal carcinoma of the prostate can evade androgen deprivation, with emergence of castrate‐tolerant cells 2017 ·British Journal of Urology ·Laura H. Porter, Kohei Hashimoto, Mitchell G. Lawrence, Carmel Pezaro, David Clouston, Hong Wang, Melissa Papargiris, Heather Thorne, Jason Li, (unknown), Anthony J. Ryan, Sam Norden, (unknown), Damien Bolton, Shomik Sengupta, Mark Frydenberg, Declan G. Murphy, Gail P. Risbridger, Renea A. Taylor	33
13	Systematic Review Links the Prevalence of Intraductal Carcinoma of the Prostate to Prostate Cancer Risk Categories 2017 ·European Urology ·Laura H. Porter, Mitchell G. Lawrence, Dragan Ilić, David Clouston, Damien Bolton, Mark Frydenberg, Declan G. Murphy, Carmel Pezaro, Gail P. Risbridger, Renea A. Taylor	72
14	The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer 2016 ·Clinical Cancer Research ·Richard J. Rebello, Eric Kusnadi, Donald P. Cameron, Helen Pearson, (unknown), Jennifer R. Devlin, Denis Drygin, Ashlee K. Clark, Laura H. Porter, John Pedersen, Shahneen Sandhu, Gail P. Risbridger, Richard B. Pearson, Ross D. Hannan, Luc Furic	61
15	Establishment of primary patient-derived xenografts of palliative TURP specimens to study castrate-resistant prostate cancer 2015 ·The Prostate ·Mitchell G. Lawrence, David Pook, Hong Wang, Laura H. Porter, Mark Frydenberg, John Kourambas, Sree Appu, (unknown), (unknown), (unknown), Sam Norden, Melissa Papargiris, Gail P. Risbridger, Renea A. Taylor	29

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact